Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 13

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 13
---
 June 30, 2025 and 2024, respectively.

NOTE
9: SEGMENT INFORMATION

The
Company operates in one business segment, focusing on the development of a novel and patented systemically administered anti-cancer and
anti-viral immunotherapy. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The
CODM assesses performance for the segment based on operating expenses as reported in the accompanying interim consolidated statements
of operations.

As
such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess
the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus
actual results is used in assessing performance of the segment.

The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company’s reportable segment for the periods presented:

 SCHEDULE OF REPORTABLE SEGMENT LOSS 

    $1  
    $2  
    $3  
    $4 

    Three
    months ended  
    Six
    months ended 

    June
    30  
    June
    30 

    2025  
    2024  
    2025  
    2024 
  
    Research
    and development: 

    External
    research and development 
    $1,687,877  
    $923,864  
    $4,003,989  
    $1,704,764 
  
    Internal
    personnel costs 
     479,237  
     790,109  
     973,965  
     1,600,351 
  
    Total research
    and development 
     2,167,114  
     1,713,973  
     4,977,954  
     3,305,115 
  
    General and
    administrative 
     2,289,649  
     2,394,912  
     4,051,368  
     4,747,009 
  
    Other income,
    net 
     (15,547) 
     (93,618) 
     (55,676) 
     (230,180)
  
    Change
    in fair value of convertible promissory notes